Exposure-QT analysis for sonidegib (LDE225), an oral inhibitor of the hedgehog signaling pathway, for measures of the QT prolongation potential in healthy subjects and in patients with advanced solid tumors.

PubWeight™: 0.75^‹?›

🔗 View Article (PMID 27663457)

Published in Eur J Clin Pharmacol on September 23, 2016

Authors

Michelle Quinlan¹, Jocelyn Zhou¹, Eunju Hurh²^,3, Dalila Sellami⁴

Author Affiliations

1: Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936-1080, USA.
2: Novartis Institutes for BioMedical Research, Inc, Cambridge, MA, USA.
3: Ionis Pharmaceuticals, Inc, Carlsbad, CA, USA.
4: Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936-1080, USA. dalila.sellami@novartis.com.

Articles cited by this ↗

Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci (2009) 3.74

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol (2015) 1.90

Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist. ACS Med Chem Lett (2010) 1.68

The cell biology of Smo signalling and its relationships with GPCRs. Biochim Biophys Acta (2006) 1.02

Articles by these authors ⇆

Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors. Cancer Chemother Pharmacol (2016) 0.76